ArticleApplied biochemistry and biotechnology2025
Neobaicalein Alleviates Retinal Damage via Microglia-Mediated Astrocyte Phenotypic Transformation.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Associations Between Dietary Flavonoid Intake and Neurodegenerative Diseases Risk: A Cross-Sectional Study.Chemical biology & drug design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neobaicalein, a natural flavonoid compound, has shown potential therapeutic effects on various neurodegenerative diseases. However, its role and the underlying mechanisms in retinal damage remain largely unexplored. A mouse model of acute ocular hypertension (AOH) was established by raising intraocular pressure to 90 mmHg for 60 min. To investigate the involvement of Annexin A3 (ANXA3), adeno-associated virus vectors were used for ANXA3 knockdown and overexpression in vivo. In vitro, cytokine cocktail, Neobaicalein and lipopolysaccharides were applied to stimulate primary mouse astrocytes and BV2 and N9 microglial cell lines, respectively. Retinal injury and cellular changes were evaluated by histological analysis, immunofluorescence, ELISA, qPCR, and Western blotting. Neobaicalein treatment (25 mg/kg) significantly preserved retinal integrity in AOH mice by increasing the thickness of the inner plexiform layer (p < 0.01) and inner nuclear layer (p < 0.01), and enhanced RGC survival (BRN3A⁺ and RBPMS⁺ cells, both p < 0.05). It markedly reduced retinal astrocyte activation (GFAP intensity, p < 0.001), decreased expression of A1 astrocytic markers (C3, GBP2), and increased A2 markers (S100A10, PTX3). Microglial activation and pro-A1 cytokine secretion were also suppressed. Neobaicalein decreased ANXA3 expression in activated microglia. Importantly, ANXA3 knockdown reproduced key protective effects of Neobaicalein, while its overexpression diminished the efficacy of Neobaicalein in alleviating AOH-induced retinal damage. These findings demonstrated that Neobaicalein confers retinal protection against AOH-induced injury by modulating the microglia-astrocyte axis via ANXA3 inhibition, highlighting a novel mechanism and therapeutic strategy for glaucomatous neurodegeneration.
Indexed as
Identifiers
40762869What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.